Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical (GB:0LER)
LSE:0LER
Teva Pharmaceutical (0LER) Share Price & Analysis
0 Followers
0LER Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.10 - $14.41
Previous Close$12.89
Volume7.86K
Average Volume (3M)81.84K
Market Cap
$14.45B
Enterprise Value$31.99B
Total Cash (Recent Filing)$3.23B
Total Debt (Recent Filing)$20.15B
Price to Earnings (P/E)-27.3
Beta1.89
Next Earnings
May 08, 2024EPS Estimate
$0.51Last Dividend Ex-Date
Nov 27, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding1,121,094,011
10 Day Avg. Volume8,478
30 Day Avg. Volume81,841
Standard Deviation0.16
R-Squared0.11
Alpha0.00160
Financial Highlights & Ratios
Price to Book (P/B)-1.03
Price to Sales (P/S)2.97
Price to Cash Flow (P/CF)3.30
P/FCF Ratio1.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.02
Enterprise Value/Gross Profit4.18
Enterprise Value/Ebitda17.60
Forecast
1Y Price Target
$15.71Price Target Upside21.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Teva Pharmaceutical News
PremiumCompany Announcements
Teva Pharmaceutical Revamps Financial Reporting Structure
Bulls Say, Bears Say
Bulls Say
Business DivestitureTeva intends to divest its API business by the first half of 2025, allowing the company to focus on its core business strengths and potentially accelerate its debt reduction efforts.
Financial GuidanceTeva expects 2024 Austedo sales of approximately $1.5 billion, marking a 25% growth, which reflects the company's strong position in the high-growth, high-margin brand.
Strategic PartnershipsThe licensing agreement with mAbxience covers multiple global markets, including Europe and the United States, suggesting a broad market potential for Teva.
Bears Say
Competitive PressuresNorth America GRx will be a significant factor, as sales have disappointed due to stiff competition against gRevlimid, which is expected to persist.
Financial ReportingTeva has revised previously reported consolidated financial statements after identifying a $132M understatement in the contingent consideration liability.
Profitability ConcernsAnalyst estimates for earnings per share (EPS) and EBITDA are below the consensus, signaling potential concerns about the company's profitability.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.83% Insiders
14.99% Mutual Funds
4.17% Other Institutional Investors
80.01% Public Companies and
Individual Investors
0LER FAQ
What was Teva Pharmaceutical’s price range in the past 12 months?
Teva Pharmaceutical lowest share price was $7.10 and its highest was $14.41 in the past 12 months.
What is Teva Pharmaceutical’s market cap?
Currently, no data Available
When is Teva Pharmaceutical’s upcoming earnings report date?
Teva Pharmaceutical’s upcoming earnings report date is May 08, 2024 which is in 10 days.
How were Teva Pharmaceutical’s earnings last quarter?
Teva Pharmaceutical released its earnings results on Jan 31, 2024. The company reported $1 earnings per share for the quarter, beating the consensus estimate of $0.768 by $0.232.
Is Teva Pharmaceutical overvalued?
According to Wall Street analysts Teva Pharmaceutical’s price is currently Undervalued.
Does Teva Pharmaceutical pay dividends?
Teva Pharmaceutical pays a Quarterly dividend of $0.07 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical dividends here
What is Teva Pharmaceutical’s EPS estimate?
Teva Pharmaceutical’s EPS estimate is $0.51.
How many shares outstanding does Teva Pharmaceutical have?
Teva Pharmaceutical has 1,120,992,400 shares outstanding.
What happened to Teva Pharmaceutical’s price movement after its last earnings report?
Teva Pharmaceutical reported an EPS of $1 in its last earnings report, beating expectations of $0.768. Following the earnings report the stock price went up 4.547%.
Which hedge fund is a major shareholder of Teva Pharmaceutical?
Among the largest hedge funds holding Teva Pharmaceutical’s share is Slate Path Capital LP. It holds Teva Pharmaceutical’s shares valued at 274M.
---
Teva Pharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.71 (21.90% Upside)
$15.71 (21.90% Upside)
Blogger Sentiment
Bullish
GB:0LER Sentiment 88%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $4.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.20%
12-Months-Change
Fundamentals
Return on Equity
-6.84%
Trailing 12-Months
Asset Growth
-1.20%
Trailing 12-Months
Company Description
Teva Pharmaceutical
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
---
0LER Company Deck
---
0LER Earnings Call
Q4 2024
0:00 / 0:00
---
0LER Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
---
0LER Stock 12 Months Forecast
Average Price Target
$15.71
▲(21.90% Upside)
Technical Analysis
Best Analysts Covering 0LER
1 Year
1 Year Success Rate
10/16 ratings generated profit
1 Year Average Return
+18.02%
assigned a buy rating 24 days ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +18.02% per trade.
---